Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein
20041.0k citationsSteven Mumm, Michael P. Whyte et al.profile →
Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification.
Countries citing papers authored by Michael P. Whyte
Since
Specialization
Citations
This map shows the geographic impact of Michael P. Whyte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael P. Whyte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael P. Whyte more than expected).
Fields of papers citing papers by Michael P. Whyte
This network shows the impact of papers produced by Michael P. Whyte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael P. Whyte. The network helps show where Michael P. Whyte may publish in the future.
Co-authorship network of co-authors of Michael P. Whyte
This figure shows the co-authorship network connecting the top 25 collaborators of Michael P. Whyte.
A scholar is included among the top collaborators of Michael P. Whyte based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Michael P. Whyte. Michael P. Whyte is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Madson, Katherine L., Cheryl R. Greenberg, Scott Moseley, Tatjana Odrljin, & Michael P. Whyte. (2015). Asfotase Alfa: Sustained Efficacy and Tolerability in Children with Hypophosphatasia Treated for 5 Years. 84.4 indexed citations
7.
Madson, Katherine L., Cheryl R. Greenberg, Agustin Melian, et al.. (2014). Asfotase Alfa: Sustained Improved Growth and Function with Extended Treatment in Children with Hypophosphatasia. 82.1 indexed citations
Whyte, Michael P., Priya S. Kishnani, C. R. Greenberg, et al.. (2012). Hypophosphatasia: Enzyme Replacement Therapy (Asfotase Alfa) Decreases TNSALP Substrate Accumulation And Improves Functional Outcomes In Affected Adolescents And Adults.. 51(1). 35.6 indexed citations
Whyte, Michael P., Steven Mumm, & Chad Deal. (2007). Adult Hypophosphatasia Treated with Teriparatide. The Journal of Clinical Endocrinology & Metabolism. 92(4). 1203–1208.117 indexed citations
Kennedy, Ann, Paul T. Christie, Brian Harding, et al.. (2003). Matrix metalloproteinase 13 (MMP13) mutation causes spondyloepimetaphyseal dysplasia (SEMD), Missouri variant. 5(18). 25–6.2 indexed citations
Lloyd, Sarah E., Michael P. Whyte, & Rajesh V. Thakker. (1997). Familial benign hypercalcaemia, Oklahoma variant (FBHok): Localisation to chromosome 19q13.. Journal of Bone and Mineral Research. 12. 161–161.1 indexed citations
16.
Dixon, Peter, C Wooding, Dorothy Trump, et al.. (1996). Seven novel mutations in the PEX gene indicate molecular heterogeneity for X-linked hypophosphataemic rickets.. Journal of Bone and Mineral Research. 11. 165–165.1 indexed citations
17.
Trump, Dorothy, et al.. (1995). LINKAGE STUDIES IN A KINDRED FROM OKLAHOMA WITH FAMILIAL BENIGN HYPOCALCIURIC HYPERCALCEMIA (FBH) INDICATE GENETIC-HETEROGENEITY AND A 3RD LOCUS FOR FBH. Journal of Medical Genetics. 32. 152–152.1 indexed citations
Whyte, Michael P., William A. Murphy, & John G. Haddad. (1981). Reactivation of healed osteolytic Paget's bone disease following cessation of synthetic human calcitonin therapy. Calcified Tissue International. 33(3).1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.